[Fatal hepatic failure in a normally developed 5-year-old boy caused by VPA monotherapy].
A five-year-old, normally developed boy who had been healthy except for an absence epilepsy prior to valproate (VPA) treatment died 16 weeks after the introduction of VPA-monotherapy due to liver failure and intractable bleeding disorder. This case emphasizes that the restriction of VPA-therapy to children of more than two years of age, on monotherapy, and without evidence of other diseases or retardation does not exclude fatal complications. Until today world-wide about 100 patients have died during VPA-treatment.
D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D002675:Child, Preschool; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy*; D006501:Hepatic Encephalopathy / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D014635:Valproic Acid
Tödliches Leberversagen bei einem altersgemäss entwickelten fünf Jahre alten Jungen unter VPA-Monotherapie.